JPRN-jRCT2080221333未知3 期
A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Subject who completed the B1321052 study as planned
排除标准
- •1.Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening
- •2.Has hypotension defined as systolic arterial pressure <90 mm Hg after sitting for 5 minutes at Screening.
研究者
相似试验
Unknown
3 期
A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial HypertensioCTRI/2009/091/000183Pfizer Limited180
已完成
不适用
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety-I270 Primary pulmonary hypertensionPrimary pulmonary hypertensionI270PER-026-09PFIZER S.A.,
未知
3 期
A Phase 3 Pharmacokinetic Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years with HypertensioPediatric hypertensionJPRN-jRCT2080222846TAKEDA PHARMACEUTICAL COMPANY LTD.6
进行中（未招募）
不适用
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaProphylaxis against Neisseria meningitidis serogroups A, C, W, and YEUCTR2014-004617-82-Outside-EU/EEAovartis Vaccines and Diagnostics SR198
已完成
3 期
A Phase 3 Multicenter, Open Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg [or Tafamidis (PF-06291826-00) 61mg] in Subjects Diagnosed with Transthyretin Cardiomyopathy (ATTR-CM))chronic heart failureNL-OMON53130Pfizer12